Related Experiment Video
Updated: Feb 18, 2026
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study
Linda J W Bosch1, Meike de Wit1, Thang V Pham1
1From Netherlands Cancer Institute, Amsterdam; VU University Medical Center, Amsterdam; MDxHealth, Herstal, and Ghent University, Ghent, Belgium; and Kennemer Gasthuis, Haarlem, the Netherlands.
Background:
The fecal immunochemical test (FIT) for detecting hemoglobin is used widely for noninvasive colorectal cancer (CRC) screening, but its sensitivity leaves room for improvement.
Objective:
To identify novel protein biomarkers in stool that outperform or complement hemoglobin in detecting CRC and advanced adenomas.
Design:
Case-control study.
Setting:
Colonoscopy-controlled referral population from several centers.
Participants:
315 stool samples from one series of 12 patients with CRC and 10 persons without colorectal neoplasia (control samples) and a second series of 81 patients with CRC, 40 with advanced adenomas, and 43 with nonadvanced adenomas, as well as 129 persons without colorectal neoplasia (control samples); 72 FIT samples from a third independent series of 14 patients with CRC, 16 with advanced adenomas, and 18 with nonadvanced adenomas, as well as 24 persons without colorectal neoplasia (control samples).
Measurements:
Stool samples were analyzed by mass spectrometry. Classification and regression tree (CART) analysis and logistic regression analyses were performed to identify protein combinations that differentiated CRC or advanced adenoma from control samples. Antibody-based assays for 4 selected proteins were done on FIT samples.
Results:
In total, 834 human proteins were identified, 29 of which were statistically significantly enriched in CRC versus control stool samples in both series. Combinations of 4 proteins reached sensitivities of 80% and 45% for detecting CRC and advanced adenomas, respectively, at 95% specificity, which was higher than that of hemoglobin alone (P < 0.001 and P = 0.003, respectively). Selected proteins could be measured in small sample volumes used in FIT-based screening programs and discriminated between CRC and control samples (P < 0.001).
Limitation:
Lack of availability of antibodies prohibited validation of the top protein combinations in FIT samples.
Conclusion:
Mass spectrometry of stool samples identified novel candidate protein biomarkers for CRC screening. Several protein combinations outperformed hemoglobin in discriminating CRC or advanced adenoma from control samples. Proof of concept that such proteins can be detected with antibody-based assays in small sample volumes indicates the potential of these biomarkers to be applied in population screening.
Primary Funding Source:
Center for Translational Molecular Medicine, International Translational Cancer Research Dream Team, Stand Up to Cancer (American Association for Cancer Research and the Dutch Cancer Society), Dutch Digestive Foundation, and VU University Medical Center.
